Indication: As a concomitant medication to the mood stabilisers for the treatment of manic epidoses associated with bipolar disorder. Also effective in maintaining clinical improvement during continuation therapy in patients who have shown an initial treatment response.
Brand name: Risperdal (Janssen-Cilag).
Regulatory status: Not available.
Launch date: Not available.